| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,095,971,000 |
| Market
Cap: |
35.19(B) |
| Last
Volume: |
19,009,931 |
Avg
Vol: |
10,501,254 |
| 52
Week Range: |
$12.82 - $31.89 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ-100 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 4.6 |
| Insider 3/6 Months : 5.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Teva Pharmaceutical Industries is a pharmaceutical company. Co. operates through three segments: North America, which includes the U.S. and Canada; Europe, which includes the European Union and certain other European countries; and International Markets, which includes all countries in which Co. operates other than those in Co.'s North America and Europe segments. Co.'s products include: AUSTEDO; AJOVY (anti calcitonin gene-related peptide); COPAXONE; BENDEKA and TREANDA; ProAir HFA; ProAir RespiClick; QVAR; QVAR RediHaler; ProAir Digihaler; ArmonAir Digihaler; AirDuo Digihaler; BRALTUS®; CINQAIR/CINQAERO; and AirDuo RespiClick.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,113 |
1,113 |
1,113 |
| Total Buy Value |
$0 |
$20,988 |
$20,988 |
$20,988 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
742,589 |
801,384 |
1,898,019 |
3,615,709 |
| Total Sell Value |
$20,130,823 |
$21,022,008 |
$39,412,282 |
$67,560,116 |
| Total People Sold |
5 |
7 |
11 |
14 |
| Total Sell Transactions |
9 |
11 |
34 |
58 |
| End Date |
2025-10-09 |
2025-07-08 |
2025-01-07 |
2024-01-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mignone Roberto |
|
– • – |
2025-12-16 |
4 |
S |
$30.24 |
$2,340,646 |
I/I |
(77,400) |
367,600 |
|
-3% |
|
| Weiss Amir |
Chief Accounting Officer |
• – – |
2025-12-16 |
4 |
S |
$30.20 |
$371,504 |
D/D |
(12,300) |
5,650 |
|
-3% |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2025-12-09 |
4 |
S |
$28.68 |
$3,311,126 |
D/D |
(115,468) |
48,384 |
|
-8% |
|
| Daniell Richard |
Exec. VP, European Commercial |
• – – |
2025-12-09 |
4 |
OE |
$16.99 |
$2,124,542 |
D/D |
115,468 |
163,852 |
|
- |
|
| Sabag Mark |
See Remarks |
• – – |
2025-12-09 |
4 |
S |
$28.70 |
$6,230,754 |
D/D |
(216,892) |
52,828 |
|
-8% |
|
| Sabag Mark |
See Remarks |
• – – |
2025-12-09 |
4 |
OE |
$18.61 |
$2,209,454 |
D/D |
118,724 |
269,720 |
|
- |
|
| Lichtenstein Chen |
|
– • – |
2025-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,804 |
4,804 |
|
- |
|
| Mignone Roberto |
|
– • – |
2025-11-26 |
4 |
S |
$26.03 |
$1,301,505 |
I/I |
(50,000) |
445,000 |
|
-18% |
|
| Fox Christine |
EVP, Head of U.S. Commercial |
• – – |
2025-11-20 |
4 |
AS |
$24.78 |
$699,523 |
D/D |
(28,229) |
63,647 |
|
27% |
|
| Fox Christine |
EVP, Head of U.S. Commercial |
• – – |
2025-11-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,492 |
91,876 |
|
- |
|
| Fox Christine |
EVP, Head of U.S. Commercial |
• – – |
2025-11-14 |
4 |
S |
$25.11 |
$753,321 |
D/D |
(30,000) |
28,384 |
|
-22% |
|
| Mignone Roberto |
|
– • – |
2025-11-06 |
4 |
S |
$24.11 |
$4,821,880 |
I/I |
(200,000) |
495,000 |
|
-27% |
|
| Weiss Amir |
Chief Accounting Officer |
• – – |
2025-11-06 |
4 |
S |
$24.44 |
$300,564 |
D/D |
(12,300) |
17,950 |
|
-27% |
|
| Mcavoy David R. |
EVP, Chief Legal Officer |
• – – |
2025-09-05 |
4 |
B |
$18.86 |
$20,988 |
D/D |
1,113 |
13,027 |
0.01 |
63% |
|
| Hughes Eric A |
See Remarks |
• – – |
2025-08-01 |
4 |
AS |
$15.16 |
$799,437 |
D/D |
(52,742) |
0 |
|
86% |
|
| Hughes Eric A |
See Remarks |
• – – |
2025-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
52,742 |
52,742 |
|
- |
|
| Jover Placid |
See Remarks |
• – – |
2025-08-01 |
4 |
S |
$15.16 |
$91,748 |
D/D |
(6,053) |
6,774 |
|
-86% |
|
| Jover Placid |
See Remarks |
• – – |
2025-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,827 |
12,827 |
|
- |
|
| Kalif Eliyahu Sharon |
EVP, Chief Financial Officer |
• – – |
2025-06-12 |
4 |
AS |
$17.08 |
$952,464 |
D/D |
(55,775) |
403,288 |
|
7% |
|
| Mignone Roberto |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
105,315 |
|
- |
|
| Elstein Amir |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
2,103,963 |
|
- |
|
| Crane Rosemary A |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
113,247 |
|
- |
|
| Zaks Tal Zvi |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
58,772 |
|
- |
|
| Vergis Janet S. |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
73,697 |
|
- |
|
| Nisen Perry |
|
– • – |
2025-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,632 |
105,315 |
|
- |
|
615 Records found
|
|
Page 1 of 25 |
|
|
1.11 (3.58%) 
